title: Antibody therapy of pediatric B-cell lymphoma.
abstract: B-cell lymphoma in children accounts for about 10% of all pediatric malignancies. Chemotherapy has been very successful leading to an over-all 5-year survival between 80 and 90% depending on lymphoma type and extent of disease. Therapeutic toxicity remains high calling for better targeted and thus less toxic therapies. Therapeutic antibodies have become a standard element of B-cell lymphoma therapy in adults. Clinical experience in pediatric lymphoma patients is still very limited. This review outlines the rationale for antibody treatment of B-cell lymphomas in children and describes potential target structures on B-cell lymphoma cells. It summarizes the clinical experience of antibody therapy of B-cell lymphoma in children and gives an outlook on new developments and challenges for antibody therapy of pediatric B-cell lymphoma.
authors.affiliation: Department of Hematology and Oncology, Wilhelmina Children's Hospital, University Medical Center Utrecht Utrecht, Netherlands.
authors.forename: Friederike
authors.initials: F
authors.lastname: Meyer-Wentrup
authors.forename: Verena
authors.initials: V
authors.lastname: de Zwart
authors.forename: Marc
authors.initials: M
authors.lastname: Bierings
keywords: cancer immunotherapy; cancer therapeutics; individualized medicine; pediatric B-cell lymphoma; therapeutic antibodies
references.citation: Nature. 1975 Aug 7;256(5517):495-7
references.pmid: 1172191
references.citation: Nat Rev Immunol. 2010 May;10(5):345-52
references.pmid: 20414207
references.citation: Nat Biotechnol. 2011 Mar;29(3):177-8
references.pmid: 21389995
references.citation: Haematologica. 2011 Mar;96(3):400-7
references.pmid: 21109686
references.citation: Blood. 2011 Apr 28;117(17):4530-41
references.pmid: 21228331
references.citation: Blood. 2008 Feb 15;111(4):1848-54
references.pmid: 18079362
references.citation: Trends Immunol. 2012 Aug;33(8):413-20
references.pmid: 22677186
references.citation: Semin Oncol. 1980 Sep;7(3):332-9
references.pmid: 7414342
references.citation: J Clin Oncol. 1993 Oct;11(10):2021-9
references.pmid: 8410126
references.citation: J Clin Oncol. 2012 Aug 1;30(22):2776-82
references.pmid: 22753910
references.citation: Blood. 2012 Apr 19;119(16):3757-66
references.pmid: 22374697
references.citation: Blood. 2012 Apr 19;119(16):3767-78
references.pmid: 22271448
references.citation: Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5652s-5660s
references.pmid: 17875803
references.citation: J Immunol. 2005 Mar 1;174(5):2453-5
references.pmid: 15728446
references.citation: J Pediatr. 2006 May;148(5):623-627
references.pmid: 16737873
references.citation: Hum Antibodies. 2010;19(1):7-13
references.pmid: 20555126
references.citation: Biol Blood Marrow Transplant. 2013 Apr;19(4):552-61
references.pmid: 23253557
references.citation: Int Immunol. 1999 Nov;11(11):1841-9
references.pmid: 10545488
references.citation: Hematology Am Soc Hematol Educ Program. 2007;:285-96
references.pmid: 18024642
references.citation: J Biol Chem. 2003 Oct 24;278(43):42427-34
references.pmid: 12920111
references.citation: Br J Haematol. 2009 Jul;146(2):171-9
references.pmid: 19466965
references.citation: Haematologica. 2012 Sep;97(9):1431-8
references.pmid: 22511498
references.citation: Leukemia. 2011 Jan;25(1):181-4
references.pmid: 20944674
references.citation: Blood. 2011 Oct 13;118(15):4053-61
references.pmid: 21673350
references.citation: Cancer Res. 2008 Oct 1;68(19):8049-57
references.pmid: 18829563
references.citation: Blood. 2000 Mar 15;95(6):2098-103
references.pmid: 10706880
references.citation: Cancer Sci. 2012 May;103(5):933-8
references.pmid: 22335424
references.citation: Br J Haematol. 2011 Nov;155(4):426-37
references.pmid: 21902688
references.citation: Am J Hematol. 2011 Feb;86(2):170-9
references.pmid: 21264899
references.citation: N Engl J Med. 2010 Nov 4;363(19):1812-21
references.pmid: 21047225
references.citation: N Engl J Med. 2012 Jun 28;366(26):2443-54
references.pmid: 22658127
references.citation: Cancer Res. 2012 Apr 1;72(7):1632-41
references.pmid: 22350416
references.citation: Science. 2004 Apr 2;304(5667):104-7
references.pmid: 15064419
references.citation: Blood. 2012 May 31;119(22):5126-32
references.pmid: 22431570
references.citation: Science. 2008 Aug 15;321(5891):974-7
references.pmid: 18703743
references.citation: Blood. 2006 Apr 1;107(7):2639-42
references.pmid: 16352811
references.citation: Blood. 2008 Mar 15;111(6):3220-4
references.pmid: 18203952
references.citation: Leukemia. 2013 Apr;27(5):1174-7
references.pmid: 22940833
references.citation: N Engl J Med. 2002 Jan 24;346(4):235-42
references.pmid: 11807147
references.citation: Blood. 2009 Apr 30;113(18):4352-61
references.pmid: 19147785
references.citation: N Biotechnol. 2011 Sep;28(5):458-63
references.pmid: 21515428
references.citation: Br J Haematol. 2012 Nov;159(3):288-98
references.pmid: 22994199
references.citation: Arthritis Rheum. 2013 Feb;65(2):314-24
references.pmid: 23124935
references.citation: J Clin Oncol. 2010 Jul 1;28(19):3115-21
references.pmid: 20516455
references.citation: Lancet Oncol. 2006 May;7(5):379-91
references.pmid: 16648042
references.citation: Leuk Lymphoma. 2006 Dec;47(12):2584-9
references.pmid: 17169802
references.citation: Nat Rev Immunol. 2010 May;10(5):317-27
references.pmid: 20414205
references.citation: Clin Cancer Res. 2009 Oct 15;15(20):6446-53
references.pmid: 19808874
references.citation: J Thromb Haemost. 2010 Jun;8(6):1201-8
references.pmid: 20175870
references.citation: Leuk Res. 2009 Mar;33(3):465-73
references.pmid: 18835037
references.citation: Br J Haematol. 2012 Mar;156(6):730-43
references.pmid: 22260323
references.citation: Blood. 2012 Jul 26;120(4):728-36
references.pmid: 22563087
references.citation: Cancer Res. 2002 Jul 1;62(13):3736-42
references.pmid: 12097283
references.citation: Blood. 2012 Jun 21;119(25):5989-95
references.pmid: 22566601
references.citation: Nat Rev Cancer. 2012 Mar 22;12(4):278-87
references.pmid: 22437872
references.citation: J Cell Biol. 1993 Jun;121(5):1121-32
references.pmid: 7684739
references.citation: Nat Rev Drug Discov. 2012 Jan 03;11(1):19-20
references.pmid: 22212672
references.citation: Ann Oncol. 2000 Jan;11(1):47-51
references.pmid: 10690386
references.citation: Clin Rheumatol. 2011 Jan;30(1):87-97
references.pmid: 21120559
references.citation: Nat Rev Cancer. 2012 Mar 22;12(4):252-64
references.pmid: 22437870
references.citation: Pediatr Blood Cancer. 2009 Feb;52(2):177-81
references.pmid: 18816698
references.citation: Clin J Am Soc Nephrol. 2011 Jun;6(6):1308-15
references.pmid: 21566104
references.citation: J Pediatr Hematol Oncol. 2010 Jul;32(5):e167-72
references.pmid: 20606544
references.citation: Br J Haematol. 2008 Jan;140(1):46-58
references.pmid: 17991300
references.citation: Lancet Oncol. 2008 Feb;9(2):105-16
references.pmid: 18226581
references.citation: Leukemia. 2012 Feb;26(2):255-64
references.pmid: 21869836
references.citation: Clin Rheumatol. 2011 Sep;30(9):1163-72
references.pmid: 21384257
references.citation: J Clin Oncol. 2008 Aug 1;26(22):3756-62
references.pmid: 18669463
references.citation: J Biol Chem. 2008 Jun 20;283(25):16971-84
references.pmid: 18426802
references.citation: J Clin Oncol. 2010 Apr 20;28(12):2085-93
references.pmid: 20308665
references.citation: Pediatr Blood Cancer. 2011 Aug;57(2):317-20
references.pmid: 21462303
references.citation: Blood. 2012 May 31;119(22):5118-25
references.pmid: 22438256
references.citation: Pediatr Transplant. 2010 Nov;14(7):896-902
references.pmid: 20642490